Evidence map›Paper›PMID 39887032›Full record

ArticleeLife2025

Synergistic effect of inhibiting CHK2 and DNA replication on cancer cell growth.

Flavie Coquel, Sing-Zong Ho, Keng-Chang Tsai, Chun-Yen Yang, Antoine Aze, Julie Devin, Ting-Hsiang Chang, Marie Kong-Hap, Audrey Bioteau, Jerome Moreaux and 5 more

Abstract read
In one paragraph

Article in eLife, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Flavie CoquelInstitut de Génétique Humaine, Univ. de Montpellier, CNRS, Montpellier, France.
Sing-Zong HoAgricultural Biotechnology Research Center, Academia Sinica, Taipei, Taiwan.ORCID https://orcid.org/0009-0008-9986-6061
Keng-Chang TsaiPh.D. Program in Medical Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.ORCID https://orcid.org/0000-0001-8277-9174
Chun-Yen YangInstitut de Génétique Humaine, Univ. de Montpellier, CNRS, Montpellier, France.
Antoine AzeInstitut de Génétique Humaine, Univ. de Montpellier, CNRS, Montpellier, France.
Julie DevinInstitut de Génétique Humaine, Univ. de Montpellier, CNRS, Montpellier, France.
Ting-Hsiang ChangAgricultural Biotechnology Research Center, Academia Sinica, Taipei, Taiwan.
Marie Kong-HapIRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier, Montpellier, France.
Audrey BioteauInstitut de Génétique Humaine, Univ. de Montpellier, CNRS, Montpellier, France.
Jerome MoreauxInstitut de Génétique Humaine, Univ. de Montpellier, CNRS, Montpellier, France.ORCID https://orcid.org/0000-0002-5717-3207
Domenico MaioranoInstitut de Génétique Humaine, Univ. de Montpellier, CNRS, Montpellier, France.ORCID https://orcid.org/0000-0003-4229-5903
Philippe PourquierIRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier, Montpellier, France.ORCID https://orcid.org/0000-0001-5326-3005
Wen-Chin YangAgricultural Biotechnology Research Center, Academia Sinica, Taipei, Taiwan.ORCID https://orcid.org/0000-0001-6410-2581
Yea-Lih Lin *'Maintenance of Genome Integrity during DNA replication' laboratory, équipe labélisée Ligue contre le Cancer, Montpellier, France.ORCID https://orcid.org/0000-0003-4063-0771
Philippe Pasero *Institut de Génétique Humaine, Univ. de Montpellier, CNRS, Montpellier, France.ORCID https://orcid.org/0000-0001-5891-0822

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer cells display high levels of oncogene-induced replication stress (RS) and rely on DNA damage checkpoint for viability. This feature is exploited by cancer therapies to either increase RS to unbearable levels or inhibit checkpoint kinases involved in the DNA damage response. Thus far, treatments that combine these two strategies have shown promise but also have severe adverse effects. To identify novel, better-tolerated anticancer combinations, we screened a collection of plant extracts and found two natural compounds from the plant,

Indexed as

Cell ProliferationCheckpoint Kinase 2DNA ReplicationNeoplasmsAnimalsCell Line, TumorChalconesDrug SynergismHumansMiceMice, Inbred NODMice, SCIDPlant ExtractsXenograft Model Antitumor AssaysChalconesCheckpoint Kinase 2CHEK2 protein, humanPlant Extractsbiochemistrycancercancer biologychemical biologyDNA repairDNA replicationhumanmousexenopus

Identifiers

PMID39887032
PMCPMC11785374

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.